Compare Quest Diagnostics Inc (DGX) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ING Groep NV — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while ING Groep NV trades at $33.15 (market cap $96.81B). The key difference: ING Groep NV is far larger — about 3.9× Quest Diagnostics Inc's market cap, and ING Groep NV pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and ING Groep NV for 93 Days on average.
| DGX | ING | |
|---|---|---|
Market Cap | $25.06B | $96.81B |
Volume | 927,361 | 2,635,505 |
Sector | Health | Financials |
52-Week High | $247.45 | $37.27 |
52-Week Low | $173.49 | $23.66 |
Typical Hold Time | 56 Days | 93 Days |
Enterprise Value | $30.82B | $236.31B |
Dividend Yield | 1.52% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
ING stock trades at $33.43, down 4.21% with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters with Q2 2026 EPS of $0.79 versus $0.75 expected. Revenue growth remains steady at $22.9B in 2025 with a robust 28.34% net margin. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations.
The stock presents a value opportunity with a reasonable P/E of 13.09 and strong profitability metrics, though negative cash flow trends and regulatory challenges in Australia warrant monitoring. Management's raised ROE target above 16% for 2027 signals confidence in continued operational improvement and strategic execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
